SLXN — Silexion Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Silexion Therapeutics, fiscal year end - December 31st, millions except per share.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | |
| Standards: | — | USG | USG | USG |
| Status: | fx Preliminary | Final | Final | Final |
| Net Income/Starting Line | — | -5.11 | -16.5 | -11.9 |
| Depreciation | ||||
| Non-Cash Items | — | 0.447 | 9.68 | 0.478 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | — | 0.087 | -1.58 | 0.601 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Cash from Operating Activities | — | -4.53 | -8.4 | -10.8 |
| Capital Expenditures | — | -0.012 | -0.022 | -0.009 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | — | 0.585 | 0 | -0.005 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | — | 0.573 | -0.022 | -0.014 |
| Financing Cash Flow Items | — | — | 2.3 | -2.34 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | — | 0.522 | 5.1 | 15.6 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | — | -3.66 | -3.38 | 4.8 |